Price Hikes Fuel Q3 Earnings Beat For Brand Name Giant

As millions of Americans continue to grapple with the economic impact of the COVD-19 pandemic, the first earnings report for the second quarter of 2020 from a Big Pharma giant demonstrates that hiking prices on American patients continues to be a profitable practice for the industry.

Today, brand name drug company Johnson & Johnson reported better than expected Q3 earnings after hiking prices earlier this year.

Johnson & Johnson’s better than expected earnings come as the company has continued to hike prices on their prescription drugs, despite a growing crisis of affordability.

Follow along as we continue to monitor Q3 earnings announcements from brand name drug companies.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.